Evidence map›Paper›PMID 40619406›Full record

SynthesisItalian journal of pediatrics2025

Meta-analysis of TB & HIV co-infection mortality rate in sub-Saharan African children, youth, and adolescents.

Fassikaw Kebede Bizuneh, Tsehay Kebede Bizuneh, Getaye Tizazu Biwota, Biruk Beletew Abate, Tilahun Gizaw Ayenew

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Italian journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fassikaw Kebede BizunehDepartment of Public Health, College of Medicine and Health Science, Debre Markos University, P.B.Box = 269, Debre Markos City, Ethiopia. fassikaw123@dmu.edu.et.ORCID http://orcid.org/0000-0002-6117-5272
Tsehay Kebede BizunehDepartment of Geography and Environmental studies, Faculty of Social Science, Bahir Dar University, P.o.Box = 72, Bahir Dar, Ethiopia.
Getaye Tizazu BiwotaDepartment of Public Health, College of Medicine and Health Science, Debre Markos University, P.B.Box = 269, Debre Markos City, Ethiopia.
Biruk Beletew AbateCollege of Health Science, School of Public Health, Woldia University, P.o.Box 400, Woldia, Ethiopia.
Tilahun Gizaw AyenewCollege of Medicine and Health Science, Jigjiga University, P.O. Box 57, Jigjiga, Somali region, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite the effectiveness of antiretroviral treatment (ART) in reducing morbidity and mortality, children and adolescents with co-infections face an elevated risk of death due to their young age and compromised immune systems. While risk factors for tuberculosis (TB) and adverse TB outcomes in HIV-infected adults are well-documented for mortality estimation, understanding mortality risks among HIV-infected children and adolescents, especially in the era of test and treatment and universal ART for all HIV-infected persons, remains limited. This study aimed to estimate the mortality rate among TB and HIV-co-infected children in Sub-Saharan African countries using SRM.

methodsWe systematically searched relevant studies from seven international electronic databases. Articles were searched using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Article searching included six electronic databases including PubMed/MEDLINE (N = 1287), Scopus (N = 447), Web of Science (N = 174), Science Direct (N = 749, Cochran (N = 57), and Google Scholar and research repository bases searching (N = 42). The quality of primary studies was evaluated using Joanna Briggs Institute (JBI) checklist. The pooled mortality rate was estimated using a weighted inverse variance random-effect meta-analysis. Heterogeneity among studies was assessed using Cochran's Q test and estimated using I2 statistic. This document is registered in Prospero (CRD420251012913).

resultIn this SRM, 16 individual studies were included. During the co-infected mortality screening of 5,098 participants, 657 deaths were reported after co-treatment started. The pooled mortality burden was estimated at 12.96% (95% CI: 8.94 to 16.98, I2 = 92.6%, P = 0.001). The majority of TB co-infected cases were newly diagnosed after ART started. The final weighted inverse variance random-effect regression indicated WHO stages III and IV (pooled HR = 4.34), poor/ fair ART adherence (pooled HR = 3.11), missed Isoniazid preventive therapy (IPT) (pooled HR = 3.07), hemoglobin levels ≤ 10 mg/dL (pooled HR = 2.84), bedridden functional status (pooled HR = 3.19), below threshold CD4 count (pooled HR = 1.80), and missed cotrimoxazole preventive therapy (CPT) (pooled AOR = 1.58) were predictors of premature death during co-infection.

conclusionIn this review, the overall pooled burden of mortality in HIV-infected children in SSA countries was high compared with the End TB Strategy target estimation. Significant predictors of mortality included WHO clinical stages III and IV, poor or fair ART adherence, missed Isoniazid preventive therapy (IPT), and hemoglobin levels ≤ 10 mg/dL. Therefore, counseling on antiretroviral therapy adherence should be strengthened; early screening and treating of anemia, screening and scaling up of IPT, critical ART drug, and nutritional counseling should be done during regular visits for caregivers to prevent premature deaths among children, youths, and adolescents during co-infection in SSA.

Indexed as

CoinfectionHIV InfectionsTuberculosisAdolescentAfrica South of the SaharaChildChild, PreschoolFemaleHumansMaleChildrenEthiopiaHIVMortalityPediatricsPredictorsTB

Identifiers

PMID40619406
PMCPMC12232751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.